Patients with preexisting liver dysfunction could benefit the most from personalized therapy for liver tumors to balance maximal tumor control and minimal risk of liver failure. We designed an individualized adaptive trial testing the hypothesis that adapting treatment based on change in liver function could optimize the therapeutic index for each patient.
H epatocellular carcinoma (HCC) is a major cause of mortality, and the incidence rate is on the rise due to viral hepatitis, alcohol use, and nonalcoholic fatty liver disease. 1 Only a minority of patients are eligible for liver transplant or resection. For remaining patients, available therapies include stereotactic body radiation therapy (SBRT), radiofrequency or microwave ablation, catheter-based therapy (transarterial chemo-embolization or radio-embolization), and systemic therapy. Most patients require sequential therapies, emphasizing the need to balance tumor control and toxic effects of each liver-directed therapy.
For patients with normal liver function, SBRT is relatively safe. However, most patients with HCC have underlying cirrhosis, so that liver-directed therapies can cause liver decompensation. After SBRT, both classical and nonclassical radiation-induced liver disease can produce substantial morbidity and up to 7% mortality. 2, 3 Patients with advanced liver disease are excluded from many trials and treatment algorithms owing to reports of toxic effects. 4, 5 Alternatively, they are treated with low doses of radiation to maintain safety, potentially at the expense of therapeutic efficacy. 6 We aimed to develop a strategy of biomarker-based individualized adaptive radiotherapy to allow delivery of the maximally aggressive safe treatment for patients with intrahepatic cancers. We found previously that subclinical decline in a patient's liver function after radiation therapy could be estimated by assessing indocyanine green (ICG) extraction, which is removed from the circulation only by the liver and thus is a direct measurement of dynamic liver function. 7, 8 Furthermore, these changes occur as early as 1 month after completion of therapy 7 and are patient-specific, consistent with individual liver sensitivity to radiation. With this biomarker of liver function, we hypothesized that we could optimize both treatment safety and effectiveness through an individualized adaptive therapy strategy that incorporates a patient's tolerance to the first portion of SBRT into a model for individualizing the second portion of SBRT. This approach, if successful, would represent a new paradigm in radiation therapy in which, instead of relying on populationbased estimates, each patient's treatment would be modified according to the individual patient's tolerance.
Methods

Patients
The trial protocol (Supplement 1) and consent forms were approved by the University of Michigan institutional review board. Eligible patients had HCC established with biopsy or American Association of Liver Disease imaging criteria or liver metastases with prior liver-directed therapy. 6 Patients could not be eligible for curative liver resection but had to have adequate performance status (Eastern Cooperative Oncology Group score ≤2) and organ function: platelet count of at least 300×10 3 μL, a blood urea nitrogen level of 40 mg/dL or less, a creatinine level of 2.0 mg/dL or less , international normalized ratio of 1.3 or less or correctable by vitamin K unless anticoagulated for another reason, and bilirubin level of less than 3 mg/dL (in the absence of obstruction or preexisting disease of the biliary tract, eg, primary sclerosing cholangitis). (To convert blood urea nitrogen to millimoles per liter, multiply by 0.357; to convert creatinine to micromoles per liter, multiply by 88.4; to convert bilirubin micromoles per liter multiply by 17.104.) There were no limitations on tumor size, vascular invasion, pretreatment Child-Pugh (CP) score, or pretreatment ICG retention. Patients could not have an iodine allergy (contained in ICG). Written informed consent was obtained from study participants prior to any study-related procedures. They were not compensated for their participation.
Treatment Schema
Prior to initiation of SBRT, patients underwent testing with ICG in our clinical research unit. Following intravenous administration, ICG is rapidly bound to plasma proteins and then selectively taken up by hepatic parenchymal cells and secreted into the bile. Blood was collected prior to ICG infusion, through 20 minutes afterward and processed in triplicate in a Clinical Laboratory Improvement Amendments-certified laboratory, as described previously. 7 The ICG retention rate at 15 minutes (ICGR15) was calculated. 7 Patients then received 3 of the 5 planned SBRT treatments, waited 4 weeks for potential subclinical liver function change and underwent repeat assessment of the ICGR15. The dose for the final 2 treatments was adjusted, from 0% to 100% of initial ( Figure 1 ). 9 If the ICGR15 was too high at 1 month to allow for treatment, patients were retested 1 month later, with the opportunity to receive further radiation if the ICGR15 decreased sufficiently. The goal of the mid-treatment adaptation was to ensure, with high probability, that the final (1 month after the end of SBRT) ICGR15 was less than 39%, which had been associated with liver failure after wedge resection. 10 During the initial part of the trial, we did not see significant toxic effects in our study patients, which we felt was because our patients were not subjected to the major systemic insults of general anesthesia and surgery. Therefore, we amended the protocol to increase the threshold from 39% to 44%. The adaptation was performed using a statistical model that predicted the final ICGR15 for an individual patient based on the current ICGR15, change in ICGR15 from baseline to mid-treatment, dose during the first course of treatment and the dose (yet to be given) during the second course of treatment. From this model, we calculated the required limit on dose for the second course of treatment so that the expected final ICGR15 would not exceed 44%. If this limit was below the planned dose, the planned dose was reduced. If this limit was greater than the planned dose, the planned dose was given. To learn from previously treated patients, the model incorporated a parameter capturing the ratio of change in the ICGR15 during the first course of treatment to the change in the ICGR15 during the last course of treatment. This parameter was updated throughout the trial as data were accumulated. Patients with a baseline ICGR15 level greater than 44% were also enrolled but were eligible to receive only the first 3 fractions unless their mid-treatment ICGR15 level was below 44%. A full mathematical description of the method is given in eMethods in Supplement 2.
Treatment Planning
The specifics of treatment planning and delivery have been described elsewhere. 11, 12 Briefly, after implantation of fiducial markers as clinically indicated, patients underwent contrastenhanced computed tomographic (CT) simulation while immobilized in a customized vacuum body mold. Active breathing control was used to eliminate respiratory motion as tolerated, with 4-dimensional CT used for the remaining patients. Tumors (gross tumor volumes) were defined on the simulation CT, with registration of magnetic resonance imaging (MRI) as necessary. For patients treated free-breathing, an internal target volume (ITV) was generated to encompass the range of motion. The gross tumor volume or internal target volume was set equal to the clinical target volume, and a standard margin of 5 mm axially and 8 mm superiorly and inferiorly was added for the planning target volume. 3, 13 SBRT was typically forward-planned, although intensity-modulated radiotherapy was used when targets and normal tissues were in close proximity and tradeoffs between them were required. The treatment course was initially planned for 5 fractions to a maximum predicted rate of radiation-induced liver disease of 15% based on a prior model, 14 or a maximum total dose of 60 Gy.
For this plan, liver function was not considered, although it would was in the mid-treatment adaptation. The dose limits to 0.55 cc of the duodenum, stomach, and heart were 30.0, 27.5, and 52.5 Gy, respectively. The chest wall dose to 30.0 cc was kept below 35.0 Gy early in the trial and relaxed to 70.0 cc later on. Dose was prescribed to the isodose surface covering 99.95% of the planning target volume , except in cases in which sparing of adjacent organs was given priority. Cone-beam CT was used for image guidance prior to every treatment.
Evaluation
Patients underwent ICG clearance testing, clinical evaluation with adverse event (CTCAE, version 4) and performance status assessment, and liver function testing 1 month after completion of SBRT. Except for the ICG, these were all repeated every 3 to 6 months for 2 years, along with evaluation with contrastenhanced liver MRI, except in patients who could not have MRI (eg, owing to a pacemaker), who were followed with contrastenhanced CT. Freedom from local progression was defined using the Response Evaluation Criteria in Solid Tumors criteria. 15 
Statistical Methods
The primary aim of the trial was to characterize efficacy of individualized SBRT in this patient population. The primary end point was local control (LC). Secondary end points included safety, overall survival (OS), and biomarkers for predicting safety and efficacy. Local control was defined as the time from start of SBRT until progression of the treated lesion. Patients without progression were censored at the earlier of last scan, liver transplant, or initiation of systemic therapy. Analyses for LC were conducted at the lesion level with robust standard errors used to account for the correlation between multiple lesions within the same patient. Local control was estimated at 1 and 2 years using the cumulative incidence function, with death as a competing risk. Overall survival was measured from start of SBRT until death or loss to follow-up. Ten patients enrolled twice in this protocol after developing new lesions and were counted separately in estimating OS. Robust standard errors were also used in OS analysis to account for intrapatient correlation among the patients enrolled twice. [16] [17] [18] Cox proportional hazards regression models were used to assess potential predictors for their relation to LC and OS. Stepwise procedures were used to build multivariate models with an α = .10 significance threshold for inclusion in the model. Local progression was included as a timedependent indicator variable in the OS analysis. 17, 18 The proportions of patients with at least a 1-or 2-point increase in CP at any point within 6 months of treatment were calculated. Statistical significance was evaluated at P ≤ .05, and all analyses were implemented using R (R Foundation) or SAS (version 9.4: SAS Inc) statistical software. The trial was designed to rule out 1-year LC rates of 65% or less. With 90 patients, the trial had greater than 80% power, based on a 1-sided α = .05 level test and a hypothesized 1-year LC rate of 80%.
Results
Patients and Treatment
Patients were 34 to 85 years of age, and 70% (63) were male. Between May 2010 and October 2014, 120 patients consented Liver function decline. Adapt radiation plan to maintain safety.
Patients with HCC or metastases with prior liver-directed therapy ICG assessment ICG reassessment 1-mo Break to participate in the trial (Figure 2) . Twenty-one patients were screen failure, and 5 patients withdrew consent prior to treatment owing to perceived difficulties traveling for treatment. Ninety patients with 116 tumors received treatment and were evaluable. Eighteen patients had more than 1 lesion treated at once (12 patients had 2, 4 had 3, and 2 had 4). Six patients were enrolled twice, and 2 patients enrolled 3 times. Baseline patient and tumor characteristics are displayed in Table 1 . Most patients had HCC and cirrhosis, typically in the setting of hepatitis C virus and/or alcohol use. The median pretreatment CP score was 6 (range, 5-9); 23% of patients were CP grade B. Median pretreatment total bilirubin level was 0.9 mg/dL (range, 0.3-3.5 mg/dL).
The median pretreatment ICGR15 was 22%, over twice the upper limit of normal. Patients had received a median of 2 liverdirected therapies (range, 0-6) prior to SBRT. Seventy had received prior transcatheter arterial chemoembolization; 36, prior radiation therapy; and 13, prior radiofrequency ablation. The median tumor diameter was 3 cm, with a maximum of 13 cm; 16 (18%) were associated with portal vein tumor thrombus. The mean liver dose was a median of 13 Gy (range, 3-30 Gy).
Treatment and Adaptation
Treatment was adapted for safety for 52 (45%) of 116 tumors. Twenty-six tumors were treated with only 3 fractions owing to an elevated pretreatment ICGR15 above the threshold for further treatment that did not decrease below 44% at the midtreatment assessment. For 26 tumors (22%), treatment was adapted based on the patient's change in ICGR15 after the initial phase of treatment, resulting in a lower dose of SBRT for the last 2 treatments. Sixty-four tumors (55%) received the full planned 5 fraction course of SBRT and did not require adaptation. The median delivered prescription dose was 49 Gy (range 23-60 Gy) (eFigure 1 in Supplement 2).
Treatment adaptation significantly altered the course of predicted decline in liver function (eFigure 2 in Supplement 2). For the patients treated with reduced dose for the final 2 of the 5 therapies, there was a significantly smaller mean increase in ICGR15 2 months posttherapy than would have been predicted with no adaptation (ICGR15 change, 9.2% vs 19.0%; P = .03).
Toxic Effects
Treatment was well tolerated with no classical radiationinduced liver disease and a lower complication rate than expected without adaptation. Grade 3 elevations in aspartate aminotransferase, alanine aminotransferase, and total bilirubin levels occurred in 1, 2, and 1 patient within 6 months of SBRT, respectively. Thirteen (14%) and 6 (7%) of patients experienced a 1-or 2-point increase in CP score within 6 months of treatment. All but 1 of these patients had cirrhosis, and all had a primary liver tumor rather than metastatic disease to the liver. Thus, in the subset of 73 patients with primary liver tumors, 13 (18%) had a 1-point increase in CP score, and 6 (8%) had a 2-point increase in CP score. One patient developed grade 2 ascites, and another developed grade 3 ascites without any other signs of radiation-induced liver disease. One patient had grade 3 duodenal bleeding adjacent to her tumor 7 months after completing therapy. All of these patients had primary liver tumors. The most common toxic effect was grade 2 fatigue in 18%. Patients who had received prior liver-directed therapy did not have a higher rate of toxic effects than those who had not.
Tumor Control and Survival
The estimated local control at 1 year was 99% (95% CI, 97%-100%) and was significantly greater than 65% (P < .001), thus achieving our primary study aim. With a median follow-up of 37 months, local control at 2 years for both HCC and metastatic disease was 95% (95% CI, 91%-99%) ( Figure 3A) . The 5 recurrent tumors were in patients without portal vein tumor thrombus. Three had HCC, 1 had metastases, and 1 had intrahepatic cholangiocarcinoma. Tumor sizes were 12, 19, 26, 30 , and 38 mm. Tumors were located in the left lobe in 2, right lobe in 1, caudate in 1, and dome in 1 patient. Pretreatment alphafetoprotein tests for patients with HCC were 2.0, 5.7, and 69.7. The number of prior liver-directed therapies in these 5 patients were 4 in 1, 3 in 1, 2 in 2, and 0 in 1. Radiation doses were 30, 33, 50, 50, and 60 Gy. Local recurrences were diagnosed 8, 18, 18, 18, and 21 months after initiation of SBRT. The median time to progression was 9 months ( Figure 3B ). These included progression of the treated tumor in 5 patients (<1%) , new tumor(s) elsewhere in the liver in 78 patients (87%), and extrahepatic progression in 40 patients (44%). At the time of progression, subsequent therapy consisted of systemic therapy in 29 patients, transcatheter arterial chemoembolization in 5 patients (<1%), additional radiotherapy in 5 patients (<1%), and radioembolization in 3 patients (<1%).
Overall survival at 1 and 2 years was 67% (95% CI, 58%-78%) and 36% (95% CI, 27%-48%) ( Figure 3C ). In univariate analysis, sex, age, number of prior liver-directed therapies, tumor histologic findings, and type of liver disease were not associated with local control or survival. Smaller tumor size, no portal vein tumor thrombus, no cirrhosis, lower baseline CP, and higher dose were associated with a longer OS. In a multivariable analysis for LC with histologic findings and total dose, higher dose was associated with better local control; however, this was not statistically significant (hazard ratio, 0.9; 95% CI, 0.8-1.01; P = .08). For OS, multivariable analysis identified fewer prior liver-directed therapies, smaller tumor size, lower baseline CP, and higher dose to be associated with longer survival ( Table 2 ). Local progression of the treated tumor was not associated with shorter survival.
Discussion
This large phase 2 trial of 90 patients at increased risk for liver damage after local therapy demonstrates that the strategy of biomarker-based individualized adaptive radiotherapy can be used to achieve both high rates of local control and a high degree of safety, rather than sacrificing one for the other. Standard radiation therapy relies solely on population-based toxicity models that limit the aggressiveness of therapy for 95% of patients based on the risk of toxic effects to the most sensitive 5%. In contrast, we have taken the approach of determining the radiation sensitivity of each patient's liver during treatment, in time to modify the remainder of the course, so that treatment can be deintensified for radiation-sensitive patients. 7, 9 This approach may represent a new paradigm in radiation therapy in which treatment is modified according to the individual patient's response rather than relying on population-based metrics. Our results are favorable for a relatively unselected group of patients. In carefully selected patients with minimal liver dysfunction, local tumor control after SBRT has approached 90% in a recent study 19 and 95% in a multi-institutional hypofractionated proton therapy study. 20 However, local control rates have generally been suboptimal, particularly for larger tumors and those recurrent after other therapiesdespite using radiation regimens associated with substantial toxic effects. 19, [21] [22] [23] Patients with preexisting liver dysfunction, particularly those with CP grade B or C cirrhosis, have had rates of radiation-induced liver disease of up to 27% and rates of CP decline of 2 or more points up to 34%, despite careful radiation treatment planning using data on populationbased, dose-volume toxic effects. 5, 6, 24 Local control was not associated with improved survival on multivariable analysis, and OS at 2 years was only 36%. This is due to the late stage at which most of our patients were treated, with a median of 2 prior treatments, which exacerbates the competing risk of progressive cirrhosis and the development of additional primary tumors through field cancerization. Thus, we would view our results as proof of principle that radiation can safely control intrahepatic cancers, and we would anticipate improved survival if radiation therapy were used earlier in the course of disease. Adjuvant treatment with sorafenib after surgery or ablation has not proven successful, 25 indicating a need for improved systemic therapies.
In this trial, we used the change in ICG clearance as a biomarker of liver function. This test has been used extensively in Asia to assess the safety of liver resections for HCC and to predict survival in critically ill patients. 8, 26 Other biomarkers are being evaluated for early detection of liver damage, including cytokines and microRNAs, although these are yet to be validated. [27] [28] [29] In addition to biologic markers that provide a global assessment of liver function and sensitivity to radiation, imaging markers are being developed for spatial assessment of liver function. 30, 31 In particular, portal venous perfusion correlates with global liver function and changes in a dose-dependent manner after radiotherapy.
Limitations
This study has several limitations. First, there was slight heterogeneity of the patient population. When designing the trial, we hypothesized that patients who had previous liver-directed therapy and resulting subclinical liver damage would be at high risk for additional dysfunction caused by radiotherapy. During the course of the trial, it became apparent that patients with metastatic tumors were at lower risk than patients with primary liver tumors and/or cirrhosis. Thus, data are presented for all patients as well as specifically those with HCC. In addition, although this is a large phase 2 trial, it has the limitation of being a single-arm, single-institution study.
Besides careful treatment planning and image-guided delivery, another potential way to further minimize liver toxic effects is to deintensify treatment for selected patients, yet not sacrifice local control. Early changes in arterial perfusion on dynamic contrast-enhanced MRI have been demonstrated to predict for tumor control, while the spatial map of portal venous perfusion parallels the distribution of liver function. It is likely that a subset of patients in the trial described herein had radiosensitive tumors that could have been controlled with lower doses of radiation. Determining the minimum dose required for tumor control is a current focus of our research; in our new clinical trial (NCT02460835), 32 patients who have a complete response after three-fifths of planned therapy are spared additional treatment and thus spared additional subclinical liver damage. Radiotherapy is also adapted based on the spatial distribution of liver function as determined with portal venous perfusion dynamic contrast-enhanced MRI, so that high-functioning portions of the liver are preferentially spared from radiation, maximizing the functional reserve. Thus, treatment is being adapted based on each patient's change in viable tumor as well as liver function to simultaneously deintensify therapy for patients who are predicted to respond, intensify therapy for patients who have more refractory tumors, and maximize posttherapy liver function, reserving function for future interventions.
Conclusions
This study demonstrates that biomarker-based individualized adaptive radiotherapy can be used to achieve both high rates of control and safety in patients with liver tumors.
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Accepted for Publication: June 7, 2017. Role of the Funder/Sponsor: The funding sources had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. However, RFA is limited by tumor size (typically ≤4 cm), number of lesions, and the geometry of tumor(s) within the liver. Furthermore, patients with HCC who have undergone previous resections or ablations may have significant, but variable, underlying liver dysfunction, which makes it difficult to design a safe and effective therapy for all patients without a full understanding of the individual patient's tolerance to treatment. Likewise, although trans-arterial chemoembolization (TACE) has been shown to be superior over best supportive care for patients with HCC and good performance status (Child A) and tumors < 6 cm, essentially all patients ultimately recur. TACE has limited efficacy for metastatic disease to the liver (other than the relatively rare neuroendocrine tumor). Thus, improved treatment approaches are needed for patients with intrahepatic cancer who cannot undergo resection or transplant.
Recent advances in radiation treatment delivery have allowed for high-precision, high-dose stereotactic radiation techniques once reserved for intracranial malignancies to be applied to extracranial sites. Preliminary results suggest excellent local control rates (above 90%) of intrahepatic malignancies treated with stereotactic body radiation therapy (SBRT)(1-3) using 60 Gy in three fractions of 20 Gy each. These studies have been carried out on previously untreated patients with metastatic tumors less than 6 cm in size.
We hypothesize that it will be possible to extend SBRT to "non-standard" patients, i.e., those who have had previous liver treatment (such as resection, TACE, RFA, or SBRT) or who have primary HCC. These patients are at risk for toxicity from the established approach of 60 Gy in three fractions. Although we have more experience with liver radiation than any institution outside of China, we still have only a limited ability to predict who will develop toxicity based solely on pretreatment characteristics, particularly for patients with HCC and cirrhosis. Therefore, we propose a new approach to SBRT in which therapy is divided into two parts/sections, with a four week assessment period between parts. This will permit us to increase the safety and efficacy of therapy by assessing the effect of the first part of therapy for the individual patient before administering the final portion of treatment. Our primary aim is to characterize the safety of the dose we deliver using this approach and, secondarily, to estimate the response rate using this approach. Our goal is to achieve the same or superior control rates with acceptable toxicity in this group of patients that has been achieved for previously untreated patients using RFA, TACE, or primary SBRT.
B. SPECIFIC AIMS
Hypothesis: SBRT can be delivered safely in "non-standard" patients (previous liver treatment and/or primary HCC) with acceptable toxicity by dividing therapy into two parts so that the individual's response to treatment can be assessed.
Primary aim:
Characterize, in patients who have had previous liver treatment or who have primary HCC, the safety and efficacy of individualized SBRT, which consists of three fractions of SBRT, a one month break, an assessment of liver function (using Indocyanine Green (IC-Green)), and two additional fractions adjusted to account for the patient's tolerance to the first 3 fractions.
Secondary aims:
2.1 Collect data on plasma biomarkers of treatment efficacy, toxicity, and liver function to plan further enhancements to individualized SBRT. Worldwide, primary liver cancer is a major health problem with more than 500,000 new cases diagnosed yearly. It is the fifth most common neoplasm, and the third most common cause of cancer-related death. (5) In some areas of Asia, HCC is the most common cause of death due to cancer. The American Cancer Society estimates that 30,890 people were diagnosed with HCC, gallbladder cancer or cholangiocarcinoma in the US in 2008. (4) The incidence has been increasing in Europe(6) and in the US(4, 7) and it is estimated that its incidence in the US will equal that currently reported in Japan within two decades. (8) An increase in the incidence of intrahepatic cholangiocarcinoma has also been reported. (9) Primary liver cancer is one of 4 cancer sites that has increased death rates between 1990 and 2004, and is the only cancer that has shown more than 10% increase (41% and 28% rate increases for males and females, respectively). (4) This disease is clearly a growing problem.
Current Therapies for unresectable intrahepatic cancer
Complete resection is the most effective therapy for HCC and bile-duct cancer. More recently, a similar role has been established for surgery in the management of CRC metastases. Surgical series have reported 25-40% 5-year survival following hepatic resection of solitary or a limited number of multiple metastases in these patients.(10-12) Unfortunately, curative surgery cannot be extended to most patients. Many patients are inoperable due to co-morbidity, and others present with disease extent that requires resections that would not leave sufficient residual functional liver parenchyma. For instance, Abdalla et al. reported the M.D. Anderson experience with hepatic resection and radiofrequency ablation (RFA). (13) Of 418 patients who were deemed resectable and were explored, only 190 patients (45%) underwent complete resection. 38% of patients underwent either RFA alone (or RFA as part of a resection): 44%, recurred in the liver. With respect to metastases to the liver, a recent Cochrane review summarized its recommendations for the treatment by stating, "There is currently insufficient evidence to support a single approach, either surgical or non-surgical, for the management of colorectal liver metastases". (14) Three major therapies have been used for these unresectable patients.
Radiofrequency Ablation (RFA)
In a prospective trial by Lencioni and colleagues (15) , 10% of 206 patients initially evaluated for RFA had contraindications based on tumor location. After these patients were excluded, 20% had an inadequate response to RFA (viable tumor remaining after 1 month). Of the patients who had an inadequate response to RFA, only approximately half of the patients were controlled by a second RFA. Finally, 10% of patients who were thought to be controlled recurred locally within 3 years. In a systematic review of the use of RFA for HCC, local failures over a 3 year period tend to average from 10 -29%, and failure elsewhere in the liver approximately 50% (16) . In the case of metastases from colorectal cancer, recurrences after RFA range from 2-39%, with other liver failures from 14-58% (16) . In all series, local failure increases with tumor size > 3-4 cm. Our experience at the University of Michigan suggests a similar or somewhat higher local failure rate (unpublished data). In this proposal, we anticipate focusing on patients who have recurred after RFA or have tumors that are not amenable to RFA, such as those abutting vasculature, lung, or bile duct.
Transcatheter Arterial ChemoEmbolization (TACE)
Although some trials and an initial randomized trial showed no difference between chemoembolization and best supportive care (17, 18) , more recent studies have begun to suggest that chemoembolization can improve survival of a subset of patients with hepatocellular carcinoma (19, 20) . A systematic review of all modern randomized trials suggests that TACE modestly prolongs survival (from approximately 16 months to 20 months), compared to best supportive case, for patients with tumors < 6 cm who have excellent performance status and do not have portal vein thrombosis (21, 22) . However, TACE is not a curative therapy and tumors typically recur even after multiple TACE administrations, suggesting that additional therapies are required. Historical series demonstrate that chemoembolization is of minimal efficacy for colorectal cancer metastatic to the liver (23) .
Radiation Therapy
In our previous series of clinical trials of focal liver radiation and concurrent HA-floxuridine as described below in Preliminary Studies, patients were treated with 3-D conformal radiotherapy (3-D CRT). In our preliminary analysis of this trial(24, 25), we found improved survival based on our predetermined phase II endpoint. More importantly, dose delivered was the most important predictive factor for survival. Indeed, approximately 20% of patients receiving >75 Gy are alive 4 years after treatment; historically that number would be very close to 0%. These data are proof of principle that focused radiation can control intrahepatic cancer, and that we are experienced in these techniques. (26) In the current study, we propose to use extracranial stereotactic body radiation therapy (SBRT). SBRT has been shown by multiple groups to be safe and effective in the treatment of colorectal metastases within the liver (1) (2) (3) (27) (28) (29) (30) (28) . Additional studies confirm these positive results both for colorectal cancer metastatic to the liver and for primary liver tumors (1, 31, 32) . A small study has shown that for patients with Childs A and Childs B liver status, 16 Gy x 3 fractions and 8 Gy x 5 fractions, respectively, can be safely delivered for tumors less than 6 cm in size(33).
Radiation Induced Liver Disease (RILD)
Attempts to deliver high dose radiotherapy to the liver have been limited by the development of RILD (34, 35) . This toxicity, initially referred to as radiation hepatitis, was first reported in the mid 1960's (36) . Symptoms generally occur 1-2 months following completion of radiotherapy and include tender hepatomegaly and weight gain secondary to ascites. Laboratory findings include elevated blood levels of alkaline phosphatase, transaminases and bilirubin. The clinical outcome ranges from mild reversible damage to rare fatality. (37) (38) (39) We were the first group to develop a quantitative model to estimate the risk of RILD based on dose to the liver, and we recently updated our parameter estimates by analyzing the results of over 200 patients treated at the University of Michigan with focal radiation (24) . This refined model will be used to quantify the risk of RILD and will guide the radiation dose selection for individuals participating in this trial. A specific toxicity criteria scale for RILD has been published following a consensus conference on late effects in normal tissue following radiation therapy and will be utilized in this study. (39) Although we developed the most accurate population-based model for predicting RILD for patients receiving fractionated radiation therapy, we would like to develop an approach that permits us to individualize therapy for patients undergoing SBRT. A major impediment to this goal is that RILD takes time to develop. Patients typically do not show an evidence of toxicity until a minimum of 2 weeks after the completion of treatment, and, more typically, at 4-6 weeks after treatment is complete. Obviously, it is too late to adjust therapy a month after therapy is completed. We hypothesize that the insertion of a 4 week period after 3 of the 5 planned fractions, and the use of clinical laboratory and imaging criteria to judge toxicity in the individual patient when it is still minor and reversible, could represent a major advance in increasing the safety of SBRT, particularly for patients with compromised liver function.
We have made substantial progress toward developing three novel techniques to individualize the functional assessment of the liver during therapy:
Extraction of indocyanine green:
Following intravenous injection, indocyanine green is rapidly bound to plasma protein, of which albumin is the principle carrier (95%). Indocyanine green is taken up from the plasma almost exclusively by the hepatic parenchymal cells and is secreted entirely into the bile. It undergoes no significant extrahepatic or enterohepatic circulation. Simultaneous arterial and venous blood estimations have shown negligible renal, peripheral, lung or cerebrospinal fluid uptake of the dye. Therefore, the serum clearance rate (determined from serial serum concentration measurements at various times after intravenous injection) can serve as a useful index of liver function, and has been used in thousands of patients to plan the extent of safe surgical resection. Our preliminary studies of patients undergoing fractionated radiation show that IC-Green is an accurate measure of radiation-induced liver dysfunction and, as a continuous measure, could be used to adjust radiation dose. 
Assessment of plasma cytokines:
RILD is caused by veno-occlusive disease, which is likely related to endothelial cell apoptosis as an initiating lesion. Radiation also induces various proinflammatory cytokines, including tumor necrosis factor-a (TNF-a) and transforming growth factor-beta 1 (40) , and hepatic microvascular pathogenesis that lead to apoptosis in the liver (41) . Elevation of TGF-beta has been associated with RILD in woman undergoing bone marrow transplantation for breast cancer (42) . In addition, an increased TNF-a production has been associated with the progression of hepatic veno-occlusive diseases in stem cell transplant patients (43) , suggesting the potential role of cytokines in radiation-induced liver apoptosis. Our preclinical studies demonstrate the TNF alpha may play a key role in radiation injury of the liver (44) . We have experience measuring cytokines in patient plasma (45) . We propose to measure these cytokines in plasma, and retrospectively assess their potential contribution to individualize our assessment of liver injury that could be used to adjust liver dose.
Assessment of clinical measures of severity of liver disease: The Model for End-Stage Liver
Disease (46) (MELD) and the Child-Turcotte-Pugh (CTP) classification are models used for the clinical assessment of patients with liver dysfunction (Appendix B). Patients with CTP classification Grade A versus Grade B appear to have increased sensitivity to radiation. Additionally, in a study of patients treated with SBRT for HCC or intrahepatic cholangiocarcinoma, 17% experienced progression from CTP Grade A to Grade B within 3 months after RT (31, 32) , suggesting that CTP may be a useful assessment of worsening liver function. MELD may perform even better than CTP at evaluating liver function (47) . We propose to record these clinical measures (MELD and CTP), and assess their potential contribution to individualize our assessment of liver injury that could be used to adjust liver dose.
In summary, we feel we are in a unique position to determine a patient's liver function approximately one month after the administration of three of five planned SBRT treatments. If the patient's liver function remains relatively stable at this point, it may be possible in future trials to administer substantially more radiation safely. If there has been some compromise of liver function, especially if this reflects a change in liver function, a more modest dose of radiation may still be safely given. If there has been a significant decrease, treatment can be stopped, and the risk of major toxicity avoided. We feel this is a unique and powerful paradigm to individualize radiation therapy now in patients undergoing SBRT using IC-Green, and that a result of this study will be to develop the assessment of TNF-alpha and TGF beta, and clinical assessment to further improve our ability to individualize therapy. prior to treatment, with IV and oral contrast if clinically appropriate. Patients will be immobilized with a body cast. Liver motion will be minimized with the use of active breathing control (ABC) or an equivalent technology when possible. Prior to each SBRT treatment, the liver tumor will be imaged and localized using either an on-board imaging orthogonal pair, using implanted fiducial markers, or a cone-beam CT scan.
D. RESEARCH DESIGN AND METHODS
Eligibility
Radiation target volumes:
The GTV will be defined using the planning CT scan or MRI. The CTV will be defined as the GTV. The PTV around the GTV/CTV will be determined based upon the immobilization device(s) used. If ABC is not used, then an approximately 0.5 cm circumferential margin for setup uncertainty, in addition to a breathing margin, will make up the PTV margin. The breathing PTV margin will be approximately 0.3 cm in the superior direction, anterior and posterior directions. The inferior margin will be the magnitude of the excursion of the diaphragm visualized during breathing, using fluoroscopy. If ABC is used (with daily localization), then the total PTV margin will be approximately 0.5 cm in superior, inferior, anterior and posterior directions and lateral directions.
3.4 SBRT Planning Guidelines -Radiation Doses: 3.4.1 PTV Target Doses 3.4.1.1 Doses will be prescribed to a peripheral covering isodose covering the PTV. Prescription isodose surface covers 99.5% of PTV. Aim to cover the PTV with an approximately 80% isodose surface (75-85%). Assuming dose is then normalized to this isodose at 100%, the minimum PTV dose will be 90%. Any dose > 110% must be within the PTV (except for adjacent tumors, in which the maximum dose outside the PTV must be < 115% (except for the patients that have UT from GI bleeding) they will be assessed one month later. If their liver status has improved, they can then undergo protocol therapy. If they have not improved they will be removed from protocol treatment.
Radiation Dose
Patients will have their initial dose prescribed according to our currently established NTCP model and SBRT practice. 3.4.4.1 Three dimensional treatment planning will be used for all patients. 3.4.4.2 Volumes of tumor and normal liver will be determined, and DVH based treatment planning will be carried out, targeted to the tumor only. We will biocorrect the normal liver dose distributions to 2 Gy equivalent fractions and then treat to an iso-NTCP level maximum of 15% computed with our models m=0.12; n=0.97 (a=1/n=1.03); TD50 metastases = 40.7 Gy; TD50 primary = 35.4 Gy). Typical radiation doses have been approximately 50 Gy in 5 fractions, 10 Gy/fraction; we expect that patients treated on this protocol will be treated with fractions sizes ranging from approximately 4.5 Gy/fraction to 15 Gy/fraction. weeks. If liver function has improved, repeat evaluation procedures listed and proceed with protocol calendar. If liver status is still poor, they will not receive fraction 4 & 5, but will continue to be seen per follow up calendar. 3 If the treatment is deemed complete after the initial 3 SBRT treatments (per section 10.1), then these items are not required. 4 Repeat grade 4 LFTs within 5-10 days following 1 st abnormal lab value. 5 Patients with hepatic toxicity (LFTs ≥ 5-20x Baseline value) will be evaluated with radiologic imaging. 6 If the patient was previously enrolled on any trial utilizing IC-Green (including this one), then an evaluation of IC-Green retention performed for the other trial may be used as the pre-treatment assessment for this enrollment, as long as it is within 4 weeks prior to initiation of this new course of SBRT. 7 Abdominal imaging to be done within 2 months of enrollment. 8 Chest imaging to be done within 1 year of enrollment.
BUN/Creatinine
X X INR X X AFP (for HCC) X X CEA (for MCRC) X X Toxicity Notation X Once X Once MELD/CTP assessment X X IC-Green
4.0
4 If the patient enrolls on a subsequent radiation treatment protocol, only the followup calendar for the subsequent study will be followed in order to avoid redundancy. DRUG INFORMATION: Indocyanine Green (IC-GREEN™) 4.1 Indocyanine Green has FDA approval for determining hepatic function and liver blood flow. Please refer to the Package Insert for completed details 4.2 Although there are currently no routine methods of estimating local function within the liver, there are established methods of measuring whole liver function. Probably the best-studied method of measuring liver function is through assessing the extraction of indocyanine green (ICGreen) (49) (50) (51) (52) . After i.v. administration, IC-Green dye is taken up from the plasma almost exclusively by the hepatic parenchymal cells and is secreted into the bile. It undergoes no significant extrahepatic or enterohepatic circulation. Simultaneous arterial and venous blood estimations have shown negligible renal, peripheral, lung, or cerebrospinal uptake of the dye. Therefore, the serum clearance rate of IC-Green serves as a reliable index of liver function. The clinical value of the IC-Green test has been demonstrated in the evaluation of donor organs for transplantation and the outcome of liver resections. Also, the IC-Green test was reported to be an early indicator of hepatic dysfunction after injury, whereby prolonged IC-Green clearance preceded an increase in serum bilirubin levels(49). Patients should take all of their medications as usual. The patient will be weighed and the dosage calculated on the basis of a recommended 0.5 mg/kg of body weight. The dose given must be within 20% of the total recommended dose. There will be approximately a 6 cc blood draw followed by rapid IV push of the IC-GREEN at time 0. Following I.V. administration via catheter, serum samples will be collected at approximately 5, 10, 15 and 20 minutes after injecting the dye. Each blood draw will be approximately 6 cc. The patient will have two different catheters one will be used for the IC-GREEN infusion, and the other catheter will be used to draw the samples. The catheter will be flushed with saline following each blood draw. 4.4.5 The IC-GREEN test will be administered by trained personnel in the Michigan Clinical Research Unit "MCRU". The dye is commercially available and will be ordered from UMHS pharmacy (formulary). Radiographic contrast agents are administered routinely in the department and it is fully equipped to treat an anaphylactic reaction, should one occur. 4.5 Contraindications 4.5.1 IC-GREEN™ contains sodium iodide and should be used with caution in patients who have a history of allergy to iodides. 4.6 Warnings 4.6.1 Anaphylactic deaths have been reported following IC-GREEN™ administration during cardiac catheterization. 4.7 Drug Interactions 4.7.1 Heparin preparations containing sodium bisulfite reduce the absorption peak of IC GREEN™ in blood and, therefore, should not be used as an anticoagulant for the collection of samples for analysis. 4.8 Adverse Effects 4.8.1 Anaphylactic or urticarial reactions have been reported in patients with or without history of allergy to iodides. If such reactions occur, treatment with the appropriate agents, e.g., epinephrine, antihistamines, and corticosteroids should be administered.
TREATMENT MODIFICATIONS
5.1 Hepatic Toxicity: Patients will be evaluated for symptoms and signs of RILD or other toxicity. 5.1.1 IC-Green: Expressed as a prolongation of the clearance time compared to pretreatment.
Refer to Section 10.1 for details on its use for treatment modifications. 5.1.2 Plasma cytokines will be measured, but will not affect dosing. 5.1.3 It is expected that a proportion of patients will have transient elevation of liver enzymes during treatment. Repeat of all Grade 4 LFTs is required within 5-10 days following the first abnormal lab value to determine if the Grade 4 levels are transient (defined here as <10 days) or persistent. Patients exhibiting hepatic toxicity ≥ 5-20x baseline LFT's will be evaluated with radiological imaging procedures to assess whether change in LFTs are due to tumor progression or treatment toxicity. Patients whose progressive liver function abnormalities while under treatment are deemed due to tumor progression will stop all protocol treatment and will be managed and followed as described in Section 9.0 (Study Monitoring). Patients with treatment induced hepatic toxicity of greater than 20x baseline elevation will not receive further protocol treatment unless and until liver function tests have returned to less than 5x patients baseline value. Patients will be evaluated for symptoms and signs of RILD or other toxicity. 5.2 Other Toxicity: The occurrence of treatment-related Grade 4 adverse events in any organ system will prompt discontinuance of protocol therapy while appropriate physical examination, laboratory, and imaging assessments are undertaken. Protocol treatment will not be resumed in the absence of recovery from adverse events of this magnitude. Once recovery to grade 2 has occurred, treatment may continue at the discretion of the treating physician.
5.3 Exceptions that will not be reported to IRB or require discontinuation of therapy: Grade 3 or 4 asymptomatic albumin levels or lymphopenia. Transient (< 48 hours) asymptomatic grade 3 fasting glucose levels in type II diabetics.
SBRT DOSE ADJUSTMENT
Each patient will be treated in two parts. In the first part, the dose will be determined using the normal tissue complication probability (NTCP) model described in Section D.3.4.2., Radiation Dose. The patient's baseline and interstage liver function assessments will be used to individualize their second part of treatment to ensure that the patient's ICG retention proportion at 15 minutes does not exceed 0.44 (53) . Accumulated data from the trial will be used to update the individualization model, as described in Section D. 9.0, Statistical Considerations. The steps for dose adjustment for each patient are:
6.1 Assess the patient's baseline ICG 15-minute retention proportion prior to SBRT, and plan five equal-sized fractions of SBRT as described in Section D.3.4.2. to a fixed probability of RILD.
6.2
Administer three fractions of SBRT at the dose described in Section 3.4. 20% increase in a lesion compared to its measurement taken at the time of maximum tumor regression. 7.5
Local control: For this study, local control is defined as the lack of progressive local disease following CR or PR, or lack of progressive local disease in patients with non-evaluable disease, who have no progressive elevation in serum tumor markers. Progression or development of new tumors within the liver but outside of the radiation field would not constitute a local control failure. 7.6 Disease-Specific Mortality: For this study, disease-specific mortality will be defined as death due to the patient's disease, or death due to treatment for the patient's disease. Time zero will be defined the day of the last treatment fraction. Expected Toxicities RT: The administration of RT may cause or aggravate nausea or vomiting. It can cause gastric or duodenal ulceration. Radiation can also cause skin irritation, fatigue, and decreased blood counts. Radiation-induced liver disease (veno-occlusive disease), including the possibility of damage severe enough to result in liver failure which could lead to death. In some patients it is not possible to avoid kidney irradiation which could produce a decrease in renal function. Careful RT planning can minimize these effects. 8. 4 Liver Toxicity Patients will be evaluated during therapy, and at 4-6 weeks, 2-month, and 4-month follow-up visits after last RT for symptoms and signs of RILD. RILD is a clinical syndrome of anicteric ascites, hepatomegaly and elevation of alkaline phosphatase (ALP) relative to other transaminases that may occur 2 weeks to 4 months following radiation to the liver. ALP must be at least 2-fold increased above the baseline ALP. If ascites develops at any time within 3 months following treatment, an abdominal CT and paracentesis with pathological evaluation of the ascitic fluid is recommended. If the ascitic fluid does not reveal malignancy and there is no evidence of disease progression in the liver or abdomen, it will be assumed that RILD has occurred. If disease progression in the liver or abdomen has occurred, no diagnosis of RILD can be made. In patients who have elevation of liver enzymes near Grade 4 levels and/or in patients with early nonspecific signs or symptoms of liver injury, close follow-up is recommended with repeat blood work. If no tumor progression is documented in these patients, liver injury will be presumed to be treatment related. 8. 5 GI Toxicity
TOXICITY CONSIDERATIONS
The dose constraints required for the normal stomach and small intestine should limit the GI toxicity observed and it is not expected that GI toxicity will be dose limiting. However, if a portion of the stomach or small intestine is treated (> 30 Gy), H2 blockers or proton pump inhibitors will be recommended to attempt to decrease the chance of late GI bleeding. Patients will be followed for GI toxicity at each follow up visit. Toxicity of all grades ≥2 measuring only the following conditions will be collected in the database: Gastritis, hepatic pain, vomiting and fatigue. However, AEs that occur intermittently can be recorded as one AE. 9.3.1.6 A serious adverse event (SAE) shall be defined as an adverse advent which fulfills one or more of the following criteria: • Results in death • Is immediately life threatening • Requires in-patient hospitalization or prolongation of existing hospitalization • Results in persistent or significant disability or incapacity • Is an important medical event that may jeopardize the patient or may require medical intervention to prevent 1 of the outcomes listed above. Any events or hospitalizations that are unequivocally due to progression of disease should not be reported as a SAE. The causality of SAEs (i.e., their relationship to study treatment) will be assessed by the investigators and will be labeled Definitely related to treatment, Probably related to treatment, Possibly related to treatment, Unlikely related to treatment or Not related to treatment. 9.3.2 Only adverse events events deemed serious and related will be reported to the IRB and the PI within 10 days of awareness of the event. All other events will be noted in the patients medical record. 9.3.3 Adverse events will no longer be reported if the patient has another liver-directed therapy or starts chemotherapy. The study specific Data and Safety Monitoring Committee (DSMC), consisting of the protocol investigators, data manager or designee and other members of the study team involved with the conduct of the trial, will meet quarterly or more frequently depending on the activity of the protocol. The discussion will include matters related to the safety of study participants (SAE/UaP reporting), validity and integrity of the data, enrollment rate relative to expectations, characteristics of participants, retention of participants, adherence to the protocol (potential or real protocol deviations) and data completeness.
At the regular DSMC meetings, the protocol specific Data and Safety Monitoring Report form will be completed. The report will be signed by the Principal Investigator or by one of the co investigators.
Data and Safety Monitoring Reports will be submitted to the University of Michigan Comprehensive Cancer Center Data and Safety Monitoring Board (DSMB) on a quarterly basis for independent Review.
STATISTICAL CONSIDERATIONS
This is a Phase II trial to characterize the safety and efficacy of individualized SRBT for patients who have had previous liver treatment or who have primary HCC. The trial endpoints are toxicity, local control, time to progression and survival; plasma biomarkers will also be collected to explore their use as tools for treatment individualization in future trials. During the current trial, an indicator of liver function, indocyanine green (ICG), will be used to identify during treatment patients who are at excess risk for radiation-induced liver disease (RILD) so that their radiation dose may be reduced. The model used for individualization will be updated as trial data accrue, so this is an adaptive trial of an individualized therapy. The planned accrual is ninety (90) evaluable patients over three years. An evaluable patient is a patient that has received their complete prescribed treatment (including those whose IC-green measurements precluded the second phase of treatment). We will continue to enroll patients until we have a total of 90 evaluable patients, by replacing non-evaluable patients.
Adaptive Estimate of Dose-Response Model
Data from previously treated patients will be represented by estimated parameters in the individualization model, which will be updated continually throughout the trial. The primary indicator of liver function at any time is the proportion of indocyanine green that is retained 15 minutes after administration, which is collected prior to any treatment, one month after the first part of treatment (three fractions), and one month after the second part of treatment (two additional fractions). The basic concept is to use the change in liver function over the first set of fractions to predict the change over the second set of fractions, reduce the dose if there is evidence that patients are less tolerant of the second set of fractions, and adjust the second fraction size for a given patient if it appears that patient's liver function will be unacceptably decreased by the fraction size originally planned. If a patient has k 0i =0.14 and k 1i =0.29, and the current estimate of * is 2.5, his Part 2 fraction size will be 60% ofhis Part 1 fraction size, since two full fractions would be expected to result in estimated k 2h = 0.294+(0.29-0.14)*2.5*2/3=0.54.
Stopping Rules
The method for monitoring binary adverse criteria in Phase IIa trials proposed by Simon, Thall and Estey(54) will be employed to monitor patients for decreased treatment efficacy.
The rule is designed to stop the trial if either the probability that the proportion of patients experiencing local progression (as defined in Section 7.6) within six months of treatment is greater than 0.3 or the probability that the proportion of patients experiencing treatment-related toxicity (as defined in Section 8.2) is greater than 0.1 exceeds 0.8. The trial will be stopped if the number of patients experiencing disease-related progression or treatment-related toxicity is greater than or equal to the values in columns 2 or three in Table 1 Table 1 Stopping rules -The trial is halted if the number of patients with local progression within six months of treatment or treatment-related toxicity is greater than or equal to the numbers in the second or third columns, respectively.
For example, if six or more out of the first ten evaluable patients experience local progression (as defined in Section 7.6) within six months after treatment, the trial must be stopped. Similarly, if five or more of the first twenty patients experience unacceptable toxicity (as defined in Section 8.2), the trial must be halted. The operating characteristics of this rule, determined by Monte Carlo simulation, are displayed in Table 2 .
Percentiles of Sample Size
True P(Progression) True P(Toxicity) P(Trial Stops Early) 10 Table 2 Operating characteristics of the stopping rule for progression and toxicity.
For instance, if the true probability of toxicity is 0.2 and the probability of local progression is 0.3, the probability the trial will stop early is 0.8, and the median number of patients treated at trial termination will equal 30. 10.3.1.1 Lesion control (absence of progression) at 1 year will be assessed as a dichotomous variable (see Section 7.6) in patients who complete therapy, and, in a secondary analysis, in all patients who undergo any per-protocol therapy. The proportion of patients achieving lesion control will be estimated with 90% exact binomial confidence intervals. An exact binomial test of the null hypothesis H o : <0.65 (where is the proportion of treatment successes) will be performed at a 1-sided 5% significance level on patients who complete treatment and patients who undergo any therapy. Secondary analyses will include evaluation of potential predictors, such as demographic and clinical factors, in logistic regression models.
10
10.3.1.2 Overall survival of patients who complete therapy and patients who receive any therapy will be described by product-limit (Kaplan-Meier) estimates of the survival function, along with 90% confidence limits. Secondary analyses will include evaluation of potential predictors, such as demographic and clinical factors, in proportional hazards regression (Cox) models.
10.3.1.3 Toxicities will be summarized with frequency tables and will be tabulated by CTCAE grade and relatedness to treatment (as assessed by the investigator or PI). The proportion of patients who receive any therapy that experience unacceptable toxicity (as defined in section 8.2) will be estimated. The distribution of indocyanine green 15 minute retention proportion at each time point, and its change over time, will be graphed; an appropriate probability function will be determined using the graph, and parameters estimated so that the expected probability of SBRT patients with and without individualization having unacceptable liver function can be determined. Baseline clinical and demographic variables will be added to determine potential patient subsets who may be more or less tolerant of the Part 1 treatment, or for whom indocyanine green assessment may be a better or worse predictor of toxicity; the form of these models will depend on the choice of the probability model.
Secondary Objective
Collect data on plasma biomarkers of treatment efficacy and toxicity and liver function to plan further enhancements to individualized SBRT.
10.3.2.1
The utility of plasma cytokines for individualizing SBRT will be explored in the same fashion as liver perfusion, above. The goal of both of these secondary analyses is to generate hypotheses and provide statistics for use in the design of subsequent experiments.
Collect data on changes in the clinical measures of severity of liver dysfunction, including the Model for End-Stage Liver Disease (MELD) and Child-Turcotte-Pugh (CTP)
10.3.2.2 MELD and CTP will be assessed and recorded at baseline, four weeks after Part 1 of SBRT, and four weeks after Part 2 of SBRT. Logistic regression will be used to determine if MELD and/or CTP, or changes in these clinical assessments, will be useful as predictors of subsequent RILD. Mixed effects models will be used to relate them to IC-Green. Because the number of patients experiencing RILD is expected to be small, these analyses will be considered exploratory.
Justification of Design
The sample size is justified in terms of the hypothesis test of lesion control in the primary objective. We expect a local control rate at 1 year of 80% and would like high power to rule out values lower than 65%. The required number of subjects to yield 80% power is 70. The power calculations are based on a 1-sided exact test at a 0.05 level.
We expect the proportions of metastatic, Child A and Child B patients to be roughly equal, so exploratory models of clinical subsets will be feasible. Other simulations (not shown) show that the estimate of the individualization parameter should be adequate after 10-20 patients. An additional 20 patients (for a total of 90) will also provide excellent pilot data for exploratory analyses of cytokines as predictors of toxicity, for use in designing the next clinical trial incorporating these into the adaptive process.
